Troponin in Heart Failure: Innocent Bystander or Harbinger of Risk?

Heart failure (HF) with reduced ejection fraction (HFrEF) is a leading contributor to morbidity and mortality.1,2 Several medical therapies are proven to extend survival, prevent hospitalizations, and improve quality of life in HFrEF.2 Yet despite their availability, patients with worsening HF have exceedingly high risk for 30-day mortality and rehospitalization.1,3 With the rising prevalence of HF and hospital readmissions globally,1 population-level screening strategies are imperative to identify and potentially mitigate adverse risk in HFrEF.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Editor's Comment Source Type: research